Targeted Therapeutics for Transthyretin amyloid cardiomyopathy: Time to Move Forward
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Cardiac Failure"
DOI: 10.1016/j.cardfail.2019.07.080
Abstract: Introduction Deposition of wild type or mutant transthyretin (TTR) amyloid fibrils causes TTR cardiac amyloidosis (ATTR-CA). Targeted therapeutics (TT) for ATTR-CA include TTR stabilizers (tafamidis, dilfunisal) and oligonucleotide drugs (Revusiran, Patisiran and Inotersen).TTR stabilizers prevent… read more here.
Keywords: targeted therapeutics; patients attr; therapeutics transthyretin; cause mortality ... See more keywords
Efficacy and safety of RNA interference therapeutics in transthyretin cardiac amyloidosis: A systematic review and meta‐analysis
Sign Up to like & getrecommendations! Published in 2025 at "European Journal of Clinical Investigation"
DOI: 10.1111/eci.70049
Abstract: RNAi therapeutics represent a promising advancement in the treatment of ATTR-CM, offering significant benefits over placebo. It demonstrated substantial improvements in survival, functional capacity, and quality of life, alongside a marked reduction in BNP levels… read more here.
Keywords: rna interference; therapeutics transthyretin; transthyretin cardiac; interference therapeutics ... See more keywords